The sale for Ambien (Zolpidem tartrate, original version) was %1.7 billion last year and the
treatment accounted for more than 64 percent of sleeping pill sales worldwide. But its
patent protection will expire in 1-2 years. Sanofi was hoping to convert 50 percent of the
Ambien users to Ambien CR before the patent on the original product expires.

Ambien is indicated for only short-term treatment of insomnia. Ambien has been shown to
decrease sleep latency and increase the duration of sleep for up to 35 days. Ambien can
be prescribed in quantiities exceeding a one-month supply. [1]

Ambien CR is non-narcotic and non-benzodiapzepine for the treatment of insomnia with a
similar safety profile to Ambien and a new indication for sleep maintensance, in addition to
sleep induction. [2] According to the news, Ambien CR is the first and only
extended-release prescription to help people with insomnia fall asleep fast without a
significant decrease in next day performance.

Ambien CR has two layers. One layer dissolves quickly to induce the effect while another
one dissolves slowly to provide a continuous sleep.

Other sleeping pills at experimental stages: indipion (Neurocrine Biosciences Inc.) and
gaboxadol (Merck and Lundbeck).

Market Competition
Transcept Pharmaceuticals announced that the FDA has accepted for review the NDA for
its IND Intermezzo, potentially indicated for the treatment of sleep maintenance insomnia. It
is a low-dose sublingual tablet formulation of benzodiazepine agonist zolpidem. [3]

It has been estimated the total non-benzodiazepine prescription market in the U.S. for the
treatment of insomnia in 2006 was approximately $3.4 billion, growing to $3.8 billion by
2011. Ambien/Ambien CR(TM) (zolpidem tartrate) and generic zolpidem tartrate are the
dominant prescription drugs totaling more than 70% of the market in 2006. [4]

                  
ALL RIGHTS RESERVED 2008

REFERENCES
[1] Ambien, buy-adipex-ambien-phentermine-online.com, Sept 6, 2005.
[2] Press Release, Ambien CR (Zolpidem Tartrate Extended-Release Tablets) CIV
Receives FDA Approval for the Treatment of Insomina. Sept 6, 2005 [3] Transcept:
Intermezzo accepted for review by FDA www.pharmaceutical-business-review.com
December 18 2008 [4] redhotpennystock.com: PAVC, NVD, SPNG, PINR, IDT, ALIN
"Redhotpennystock.com alert" www.tradingmarkets.comDecember 22, 2008

                                              
HOME
Ambien CR - A Sleeping Pill
US FDA approved Sanofi-Aventis' Ambien CR for insomina. The marketing approval will allow
Sanofi-Aventis to launch Ambien CR this summer to compete with Sepracor's Lunesta and
Takeda's Rozerem.
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS, SUPPLEMENTS,